Is the population dilemma difficult to solve, will the auxiliary reproduction be a key?

Auxiliary Reproductive Innovation Development Forum 2022: Population policy, medical insurance trends and institutional development

brief introduction

In 2021, the natural population growth rate was 0.34 ‰, a decrease of 1.11 thousand points from 2020. China officially entered the era of zero -growth population. With the growth of zero population, infertility issues are high.

Because of the long -term only child policy, elderly women infertility has been ignored: After the implementation of the comprehensive two -child policy in 2015, the fertility ratio of elderly women (generally defined as 35 years old and above) in the third -level hospital was 12.54%increased to 17.43%in 2017; almost every 5 or 6 couples had a couple infertility, and auxiliary reproductive technology was considered one of the most effective ways to treat infertility.

Under the favorable population policy, the auxiliary reproductive industry is accelerating. With the rise in infertility, the auxiliary reproductive service market has attracted much attention, and the capital market is extremely optimistic. At the same time, relevant local government departments have recently stated that they have paid attention to the entry of assisted reproductive technology to enter medical insurance.

Forum details

On June 17, 2022, Jianzhi Bureau will join hands with VB100 and Arterius Network to hold the 6th Future Medical 100 Fortune 100 Assistance Reproductive Innovation and Development Forum. The forum brings together industry authority and enterprise representatives, focusing on relevant policies and industries, and diverse forms such as keynote speeches and ritual releases. Through in -depth discussions of experts, we jointly promote the development of the auxiliary reproductive industry and help achieve the goal of healthy China 2030.

This forum starts with an auxiliary reproductive policy analysis, trying to comprehensively sort out from the upstream to the downstream of the industry, combines new policy changes, dismantle the opportunities and challenges of various links and segmented categories on the chain, and for the development direction of the Chinese auxiliary reproductive industry in China Provide forward -looking thinking.

Forum content

At that time, the Jianzhi Bureau will first release a heavy survey of the "China Assistance Reproductive Policy Report" (2022) for the first time. Sun Tao, deputy editor -in -chief of the Jianzhi Bureau, will make a professional interpretation at the conference. Reporting researchers visited many industry authorities and industry experts, and obtained a lot of first -hand information and depth views. The report focuses on the three major sectors of medical insurance problems, regulatory issues, and license issues that assisted reproductives, and gives more comprehensive data; more sensitive policy smell presents exclusive views and expectations. In this report, we are particularly concerned about the assisted reproductive income into medical insurance issues, and the devil is in the details.

Yuan Fengming, executive director of the China Hospital Association, former party committee secretary of the People's Hospital of Peking University, and Yuan Fengming, the ultrasound marketing manager of Mai Rui Medical China, will bring a special speech to the forum. Liu Jiayin, former director of the Reproductive Center of the People's Hospital of Jiangsu Province, Kuang Yanping, Director of the Ninth People's Hospital of Shanghai Jiaotong University Medical College, Zhang Hanwang, director of the Chief Physician of the Reproductive Medicine Center of Tongji Hospital, Duan Tao, Chief Strategy of Jinxin Reproductive Reproductive Xiao Huiru, the academic manager of the Department of Clinical Academic Ministry of Products, and the founder of He Fang Fang Fang Fang, will share with us the practice exploration of the auxiliary reproductive field.

Fan Xiaoyu, a senior researcher at the Eggs Shell Research Institute, will also interpret the "2022 Auxiliary Reproductive Industry Research: Research on the 2022 Auxiliary Reproductive Industry: Policy Bonus will become the driving force that stimulates the 800 billion markets".

- END -